

UPDATE ON CHOCOLATE TOUCH®

Key Points:

- The FDA has approved the Chocolate Touch® Drug-coated Balloon PTA Catheter, developed by the Group for the treatment of patients with peripheral artery disease in the superficial femoral artery and the popliteal artery
- Marks significant step toward unlocking the Post-Closing Payments from G Vascular of at least US\$16.1 million

SINGAPORE, 14 November 2022 – Quantum Healthcare Limited, (the “**Company**”, and together with its subsidiaries, the “**Group**”), is a premier healthcare group based primarily in Singapore.

The Board of Directors (“**Board**”) of the Company refers to the announcements made by the Company’s wholly owned subsidiary, QT Vascular Ltd. (“**QTV**”), dated 13 July 2020, 27 August 2020, 30 August 2020 and 17 December 2021 and the circular to shareholders in relation to the disposal of Chocolate Touch® Drug-coated Balloon PTA Catheter by the Group to G Vascular Private Limited (“**G Vascular**”) dated 13 July 2020 and the circular to shareholders dated 24 December 2021 (the “**December 2021 Circular**”). Unless otherwise defined, all capitalised terms used herein shall bear the same meanings ascribed to them in the December 2021 Circular.

The Company is pleased to announce that on 11 November 2022, the United States Food and Drug Administration (“**FDA**”) has given pre-market approval (“**PMA**”) for the Chocolate Touch® Drug-coated Balloon PTA Catheter for the treatment of patients with peripheral artery disease in the superficial femoral artery and the popliteal artery.

As at the date of this announcement, G Vascular has paid US\$5.9 million (which comprised Closing Payment of US\$4.9 million and assumed liabilities of US\$1 million) to the Group. The PMA received from the FDA marks a significant step towards unlocking the Post-Closing Payment of at least US\$16.1 million from G Vascular as indicated in the circular dated 13 July 2020 and the Proposed Distribution as indicated in the December 2021 Circular respectively. The Post-Closing Payment will be unlocked either upon sale of Chocolate Touch® asset to other parties or commercial sale of Chocolate Touch®, subject to detailed terms as set out in the December 2021 Circular.

~~ End ~~

Cautionary Note on Forward-Looking Statements

All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as “expect”, “anticipate”, “believe”, “estimate”, “intend”, “project”, “plan”, “strategy”, “forecast” and similar expressions or future or conditional verbs such as “if”, “will”, “would”, “should”, “could”, “may” and “might”. These statements reflect the Company’s current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company does not undertake any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

This announcement has been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (“Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “Exchange”) and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.